Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
← catalyst calendarNCT03339128 · readout ≤ 134 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
95estimated
Sites
46
Countries
Bulgaria, Canada, Germany +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-11-15 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2017-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Irritable Bowel Syndrome
Interventions
- Drug: Eluxadoline — also filed as Viberzi
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in stool consistency averaged over the 4-week Treatment Period
measured Baseline (2 Weeks prior to randomization) to Week 4
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed